BRAF35 Polyclonal Antibody

$Paraformaldehyde-fixed, paraffin embedded mouse brain; Antigen retrieval by boiling in sodium citrate buffer (pH6) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 30 minutes; Blocking buffer (normal goat serum) at 37\u00b0C for 20min; Antibody incubation with BRAF35 Polyclonal Antibody, Unconjugated (bs-12883R) at 1:200 overnight at 4\u00b0C, followed by a conjugated secondary and DAB staining.$

Paraformaldehyde-fixed, paraffin embedded mouse brain; Antigen retrieval by boiling in sodium citrate buffer (pH6) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 30 minutes; Blocking buffer (normal goat serum) at 37\u00b0C for 20min; Antibody incubation with BRAF35 Polyclonal Antibody, Unconjugated (bs-12883R) at 1:200 overnight at 4\u00b0C, followed by a conjugated secondary and DAB staining.

Applications

WB
ELISA
IHC-P
IHC-F
IF(IHC-P)
IF(IHC-F)
IF(ICC)

Reactivity

Mouse

Predicted Reactivity

Human
Rat
Cow

Overview
Catalog #	bs-12883R
Product Name	BRAF35 Polyclonal Antibody
Applications	WB ELISA IHC-P IHC-F IF(IHC-P) IF(IHC-F) IF(ICC)
Reactivity	Mouse
Predicted Reactivity	Human, Rat, Cow
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	KLH conjugated synthetic peptide derived from human BRAF35
Immunogen Range	1-100/317
Clonality	Polyclonal
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.
Target
Gene ID	10362
Subcellular location	Nucleus
Synonyms	BRAF25; BRAF35; BRCA 2 Associated Factor 35kDa; BRCA2 associated factor 35; BRCA2-associated factor 35; High Mobility Group Protein 20B; HM20B_HUMAN; HMG 20B; HMG box containing protein 20B; HMG box-containing protein 20B; HMG domain-containing protein 2; HMG domain-containing protein HMGX2; hmg20b; HMGX2; PP7706; pp8857; SMARCE1 related protein; SMARCE1-related protein; SMARCE1r; sox like; Sox like transcriptional factor; Sox-like transcriptional factor; SOXL; Structural DNA binding protein BRAF35; Structural DNA-binding protein BRAF35; SWI/SNF related; SWI/SNF related matrix associated actin dependent regulator of chromatin subfamily E member 1 related; SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1-related.
Background	The breast cancer susceptibility gene (BRCA1) localizes to chromosome 17q. Mutations within this gene account for approximately 45% of families with high incidence of breast cancer and at least 80% of families with increased incidence of both early-onset breast cancer and ovarian cancer. A second breast cancer susceptibility gene, BRCA2, located on chromosome 13q12-13, also confers a high incidence of breast cancer, but unlike BRCA1, BRCA2 does not confer a substantially elevated risk of ovarian cancer. The BRCA2-Associated Factor 35 (BRAF35) protein forms a complex with BRCA2, which associates with condensed chromatin during histone H3 phosphorylation. BRAF35 expression levels are highest in proliferating tissues and parallel BRCA2 expression patterns. The structure of BRAF35 includes a kinesin-like coiled coil domain and a nonspecific DNA binding HMG domain. The chromatin localization of BRAF35 and antibody microinjection studies indicate a role for the BRAF35/BRCA2 complex in cell cycle regulation.
Application Dilution
WB	1:300-5000
ELISA	1:500-1000
IHC-P	1:200-400
IHC-F	1:100-500
IF(IHC-P)	1:50-200
IF(IHC-F)	1:50-200
IF(ICC)	1:50-200